Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Feb
03
Today In Oncology
Deep Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
Novel HER2-Targeted Bispecific Benefits Outcomes in Gastroesophageal Cancer
Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
Head and Neck Cancer How Does Genetic Ancestry Impact Tumor Genomics
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo